Lenvaxen 4 (Lenvatinib) 4 mg Capsules

Indicated for the treatment of adult patients with:

• 🔹 Hepatocellular Carcinoma (HCC): First-line treatment for unresectable liver cancer.
• 🔹 Differentiated Thyroid Cancer (DTC): Locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.
• 🔹 Renal Cell Carcinoma (RCC): In combination with everolimus for advanced kidney cancer.
• 🔹 Endometrial Carcinoma: In combination with pembrolizumab for advanced endometrial carcinoma.

Packaging: 4 mg capsules.

⚠️ ADMINISTRATION PROTOCOL (For HCC/Liver Cancer):

• Weight-based dosing:
  — Body weight ≥ 60 kg: 12 mg (3 capsules) once daily.
  — Body weight < 60 kg: 8 mg (2 capsules) once daily.
• For Thyroid Cancer (DTC): Recommended dose is 24 mg (6 capsules) once daily.
• Timing: Take orally once daily, at the same time each day, with or without food.
• Administration: Swallow whole. Do not open, crush, or chew the capsule.

• Hypersensitivity to Lenvatinib.
• Pregnancy and breastfeeding (teratogenic effects).
• Severe hepatic impairment (Child-Pugh C) or severe renal impairment require careful monitoring.

Common adverse reactions include:

• 🩸 Cardiovascular: Hypertension (high blood pressure) is very common; proteinuria.
• 📉 Dermatologic: Palmar-plantar erythrodysesthesia (Hand-Foot Syndrome) — redness/pain on palms and soles.
• 🌀 Gastrointestinal/General: Diarrhea, fatigue, decreased appetite, weight loss, dysphonia (hoarseness).
• Patients should monitor blood pressure regularly.